Boehringer Ingelheim got approval of a supplemental New Drug Application (sNDA) for Gilotrif (afatinib) tablets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease
Posted on19 Apr 2016
Tagsafatinib, Gilotrif, head to head trial, LUX-Lung 8 trial, sNDA, supplemental New Drug Application
Comments0
Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Gilotrif (afatinib)... Read More